The current nosological concept of α-synucleinopathies characterized by the presence of Lewy bodies (LBs) includes Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), for which the term "Lewy body disease" (LBD) has recently been proposed due to their considerable clinical and pathological overlap. However, even this term does not seem to describe the true nature of this group of diseases. The subsequent discoveries of α-synuclein (αSyn), SNCA gene, and the introduction of new immunohistochemical methods have started intensive research into the molecular-biological aspects of these diseases. In light of today's knowledge, the role of LBs in the pathogenesis and classification of these nosological entities remains somewhat uncertain. An increasingly more important role is attributed to other factors as the presence of various LBs precursors, post-translational αSyn modifications, various αSyn strains, the deposition of other pathological proteins (particularly β-amyloid), and the discovery of selective vulnerability of specific cells due to anatomical configuration or synaptic dysfunction. Resulting genetic inputs can undoubtedly be considered as the main essence of these factors. Molecular-genetic data indicate that not only in PD but also in DLB, a unique genetic architecture can be ascertained, predisposing to the development of specific disease phenotypes. The presence of LBs thus remains only a kind of link between these disorders, and the term "diseases with Lewy bodies" therefore results somewhat more accurate.

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Clinical Genetics University Hospital Palacky University Olomouc Czech Republic

Department of Neurology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Neurology Santa Maria University Hospital Terni Italy

Department of Neurology University Hospital Palacky University Olomouc Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Prague Czech Republic

The Neuroscience Institute Department of Neurology and Psychiatry University of Santo Tomás Hospital Manila Philippines

Zobrazit více v PubMed

Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res. Bull. 2016;126:238–292. doi: 10.1016/j.brainresbull.2016.08.018. PubMed DOI

Kovacs GG. Molecular pathology of neurodegenerative diseases: principles and practice. J. Clin. Pathol. 2019;72:725–735. doi: 10.1136/jclinpath-2019-205952. PubMed DOI

Compta Y, et al. Lewy – and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134:1493–1505. doi: 10.1093/brain/awr031. PubMed DOI PMC

Kovacs GG, et al. Non-alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365–384. doi: 10.1007/s00401-013-1157-y. PubMed DOI

Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease dementia: current concepts and controversies. J. Neural Transm. 2018;125:615–650. doi: 10.1007/s00702-017-1821-9. PubMed DOI

Kovacs GG. Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases? Curr. Opin. Neurol. 2019;32:279–291. doi: 10.1097/WCO.0000000000000664. PubMed DOI

Das S, Zhang Z, Ang LC. Clinicopathological overlap of neurodegenerative diseases: a comprehensive review. J. Clin. Neurosci. 2020;78:30–33. doi: 10.1016/j.jocn.2020.04.088. PubMed DOI

Geut H, et al. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol. Commun. 2020;8:39. doi: 10.1186/s40478-020-00914-9. PubMed DOI PMC

Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale fo two proteins. Ann. Neurol. 2006;59:449–458. doi: 10.1002/ana.20819. PubMed DOI

Foguem C, Manckoundia P. Lewy body disease: clinical and pathological “overlap syndrome“ between synducleinopathies (Parkinson disease) and tauopathies (Alzheimer disease) Curr. Neurol. Nerosci. Rep. 2018;18:24. doi: 10.1007/s11910-018-0835-5. PubMed DOI

Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology. 2001;57:1497–1499. doi: 10.1212/WNL.57.8.1497. PubMed DOI

Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? J. Neurol. Neurosurg. Psychiatry. 2002;73:529–534. doi: 10.1136/jnnp.73.5.529. PubMed DOI PMC

Litvan I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 2003;18:467–486. doi: 10.1002/mds.10459. PubMed DOI

Postuma RB, et al. MDS clinical diagnostic crietria for Parkinson’s disease. Mov. Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424. PubMed DOI

Mensikova K, Tuckova L, Ehrmann J, Kanovsky P. Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia. Medicine. 2016;95:e5237. doi: 10.1097/MD.0000000000005237. PubMed DOI PMC

Höglinger G, et al. Clinical diagnosis of progresive supranuclear palsy: The Movement Disorders Society Criteria. Mov. Disord. 2017;32:853–864. doi: 10.1002/mds.26987. PubMed DOI PMC

Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front. Neurol. 2018;23:156. doi: 10.3389/fneur.2018.00156. PubMed DOI PMC

Rizzo G, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2018;89:358–366. doi: 10.1136/jnnp-2017-316844. PubMed DOI

Mc Keith IG, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743–755. doi: 10.1212/WNL.0000000000009323. PubMed DOI PMC

Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503. doi: 10.1212/WNL.0b013e31827f0fd1. PubMed DOI PMC

Chare L, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J. Neurol. Neurosurg. Psychiatry. 2014;85:866–871. doi: 10.1136/jnnp-2013-306948. PubMed DOI

Höglinger GU, Respondek G, Kovacs GG. New classification of tauopathies. Rev. Neurol. 2018;174:664–668. doi: 10.1016/j.neurol.2018.07.001. PubMed DOI

Respondek G, Levin J, Höglinger GU. Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Curr. Opin. Neurol. 2018;31:448–454. doi: 10.1097/WCO.0000000000000581. PubMed DOI

Jabbari E, et al. Diagnosis accross the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol. 2020;77:377–378. doi: 10.1001/jamaneurol.2019.4347. PubMed DOI PMC

McCann H, Stevens CH, Cartwright H, Halliday GM. α-synucleinopathy phenotypes. Park. Relat. Disord. 2014;20S1:S62–S67. doi: 10.1016/S1353-8020(13)70017-8. PubMed DOI

Caproni S, Colosimo C. Diagnosis and differential diagnosis of Parkinson disease. Clin. Geriatr. Med. 2020;36:13–24. doi: 10.1016/j.cger.2019.09.014. PubMed DOI

Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166. PubMed DOI

Spillantini MG, Goedert M. Neurodegeneration and the ordered assembly of α-synuclein. Cell Tissue Res. 2018;373:137–148. doi: 10.1007/s00441-017-2706-9. PubMed DOI PMC

Riederer P, et al. α-synuclein in Parkinson’s disease: causal or bystander? J. Neural Transm. 2019;126:815–840. doi: 10.1007/s00702-019-02025-9. PubMed DOI

Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versusu non-Mendelian inheritance. J. Neurochem. 2016;139:56–74. doi: 10.1111/jnc.13593. PubMed DOI PMC

Puschmann A. New genes causing hereditary Parkinson’s disease or parkinsonism. Curr. Neurol. Neurosci. Rep. 2017;17:66. doi: 10.1007/s11910-017-0780-8. PubMed DOI PMC

Singleton AB, Hardy J. Progress in the genetic analysis of Parkinson’s disease. Hum. Mol. Gen. 2019;28:215–218. doi: 10.1093/hmg/ddz183. PubMed DOI PMC

Weissbach A, Wittke C, Kasten M, Klein C. “Atypical“ Parkinson’s disease – genetic. Int. Rev. Neurobiol. 2019;149:207–237. doi: 10.1016/bs.irn.2019.10.011. PubMed DOI

Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 2020;16:97–107. doi: 10.1038/s41582-019-0301-2. PubMed DOI

Wilson GR, et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology. Am. J. Med. Genet. 2014;95:729–735. PubMed PMC

Butcher NJ, et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol. 2013;70:1359–1366. doi: 10.1001/jamaneurol.2013.3646. PubMed DOI PMC

Takao M, et al. Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology. BMJ Case Rep. 2011;2011:pii: bcr0120113685. PubMed PMC

Emre M, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 2007;22:1689–1707. doi: 10.1002/mds.21507. PubMed DOI

Mori H. Pathological substrate of dementia in Parkinson’s disease-its relation to DLB and DBLD. Parkinsonism Relat. Disord. 2005;11:S41–S45. doi: 10.1016/j.parkreldis.2005.02.012. PubMed DOI

Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta. 2009;1792:730–740. doi: 10.1016/j.bbadis.2008.07.006. PubMed DOI

Hansen DS, et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia. Neuropathol. Appl. Neurobiol. 2021;47:143–156. doi: 10.1111/nan.12648. PubMed DOI

Braak H, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 2003;24:197–211. doi: 10.1016/S0197-4580(02)00065-9. PubMed DOI

Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson’s disease. Neuropathology. 2020;40:415–425. doi: 10.1111/neup.12691. PubMed DOI

Attems J, et al. Neuropathological consensus criteria for the evaluation of Lewy body pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141:159–172. doi: 10.1007/s00401-020-02255-2. PubMed DOI PMC

Bove C, Travagli RA. Neurophysiology of the brainstem in Parkinson’s disease. J. Neurophysiol. 2019;121:1856–1864. doi: 10.1152/jn.00056.2019. PubMed DOI PMC

Keir LHM, Breen DP. New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease. J. Neurol. 2020;267:288–294. doi: 10.1007/s00415-019-09651-z. PubMed DOI PMC

Tremblay C, Mei J, Frasnelli J. Olfactory bulb surroundings can help to distinguish Parkinson’s disease from non-parkinsonian olfactory dysfunction. Neuroimage Clin. 2020;28:102457. doi: 10.1016/j.nicl.2020.102457. PubMed DOI PMC

Adler CHH, et al. Unified staging system for Lewy body disorders: clinicopathologic correlations ond comparison to Braak staging. J. Neuropathol. Exp. Neurol. 2019;78:891–899. doi: 10.1093/jnen/nlz080. PubMed DOI PMC

Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä S. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol. 2000;100:285–290. doi: 10.1007/s004019900168. PubMed DOI

Jellinger KA. Formation and development of Lewy pathology: a critical update. J. Neurol. 2009;256:S270–S279. doi: 10.1007/s00415-009-5243-y. PubMed DOI

Gibb WRG, Lees AJ. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 1988;51:745–752. doi: 10.1136/jnnp.51.6.745. PubMed DOI PMC

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 1992;55:181–184. doi: 10.1136/jnnp.55.3.181. PubMed DOI PMC

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–870. doi: 10.1093/brain/awf080. PubMed DOI

Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–134. doi: 10.1007/s00441-004-0956-9. PubMed DOI

Braak H, et al. Pathology associated with sporadic Parkinson’s disease-where does it end? J. Neural Transm. 2006;70:89–97. PubMed

Batla A, et al. Markedly asymmetric presentation in multiple system atrophy. Parkinsonism Relat. Disord. 2013;19:901–905. doi: 10.1016/j.parkreldis.2013.05.004. PubMed DOI

Mensikova K, et al. Progressive supranuclear palsy phenotype mimicking synucleinopathies. J. Neurol. Sci. 2013;329:34–37. doi: 10.1016/j.jns.2013.03.008. PubMed DOI

Mensikova K, et al. Atypical parkinsonism of progressive supranuclear palsy-parkinsonism (PSP-P) phenotype with rare variants in FBXO7 and VPS35 genes associated with Lewy body pathology. Acta Neuropathol. 2019;137:171–173. doi: 10.1007/s00401-018-1923-y. PubMed DOI

Respondek G, Stamelou M, Höglinger GU. Classification of atypical parkinsonism per pathology versus phenotype. Int. Rev. Neurobiol. 2019;149:37–47. doi: 10.1016/bs.irn.2019.10.003. PubMed DOI

Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch. Neurol. 1999;56:33–39. doi: 10.1001/archneur.56.1.33. PubMed DOI

Palermo G, Del Prete E, Bonuccelli U, Ceravolo R. Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies. J. Neurol. 2020;267:3444–3456. doi: 10.1007/s00415-020-09985-z. PubMed DOI PMC

Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol. 2003;2:229–237. doi: 10.1016/S1474-4422(03)00351-X. PubMed DOI

Guo L, Itaya M, Takanashi M, Mizuno Y, Mori H. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Park. Relat. Disord. 2005;11:305–309. doi: 10.1016/j.parkreldis.2005.02.005. PubMed DOI

Aldridge G, Birnschein A, Denburg NL, Narayanan NS. Parkinson’s disease dementia and dementia with Lewy bodies have similar neuropsychological profiles. Front. Neurol. 2018;9:123. doi: 10.3389/fneur.2018.00123. PubMed DOI PMC

McKeith IG, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113–1124. doi: 10.1212/WNL.47.5.1113. PubMed DOI

McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: Third Report of the DLB Consortium. Neurology. 2005;65:1863–1872. doi: 10.1212/01.wnl.0000187889.17253.b1. PubMed DOI

McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies. Fourth Consensus Report of the DLB Consortium. Neurology. 2017;89:88–100. doi: 10.1212/WNL.0000000000004058. PubMed DOI PMC

Kaur B, et al. Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies. Alzheimer Dis. Assoc. Disord. 2013;27:226–232. doi: 10.1097/WAD.0b013e31826f040d. PubMed DOI PMC

Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy bodies dementias. Lancet. 2015;386:1683–1697. doi: 10.1016/S0140-6736(15)00462-6. PubMed DOI PMC

Outeiro TF, et al. Dementia with Lewy bodies: an update and outlook. Mol. Neurodegener. 2019;14:5. doi: 10.1186/s13024-019-0306-8. PubMed DOI PMC

Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res. Ther. 2014;6:46. doi: 10.1186/alzrt274. PubMed DOI PMC

Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum. 2016;22:435–463. PubMed PMC

Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and dementia with Lewy bodies. F1000Res. 2017;6:1604. doi: 10.12688/f1000research.11725.1. PubMed DOI PMC

Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol. 2010;120:131–143. doi: 10.1007/s00401-010-0711-0. PubMed DOI PMC

Rohan Z, Milenkovic I, Lutz MI, Matej R, Kovacs GG. Shared and distinct patterns of oligodendroglial response in synucleinopathies and tauopathies. J. Neuropathol. Exp. Neurol. 2016;75:1100–1109. doi: 10.1093/jnen/nlw087. PubMed DOI

Colom-Cadena M, et al. Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies. Brain. 2017;140:3204–3214. doi: 10.1093/brain/awx275. PubMed DOI PMC

Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain. Brain. 2015;138:1642–1657. doi: 10.1093/brain/awv040. PubMed DOI PMC

Postuma RB, et al. Abolishing the 1-year rule: how much evidence will be enough? Mov. Disord. 2016;31:1623–1627. doi: 10.1002/mds.26796. PubMed DOI

van Steenoven I, et al. Cerebrospinal fluid Alzheimer’s disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort. J. Alzheimers Dis. 2016;54:287–295. doi: 10.3233/JAD-160322. PubMed DOI PMC

Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson’s disease dementia. Int. J. Geriatr. Psychiatry. 2011;26:100–105. doi: 10.1002/gps.2496. PubMed DOI

Irwin DJ, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16:55–65. doi: 10.1016/S1474-4422(16)30291-5. PubMed DOI PMC

Kurata T, et al. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. J. Neurosci. Res. 2007;85:2246–2252. doi: 10.1002/jnr.21352. PubMed DOI

Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3betacatalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J. 2009;23:2820–2830. doi: 10.1096/fj.08-120410. PubMed DOI PMC

Anderson JP, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006;281:29739–29752. doi: 10.1074/jbc.M600933200. PubMed DOI

Swirski M, et al. Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease. Alzheimers Res. Ther. 2014;6:77. doi: 10.1186/s13195-014-0077-y. PubMed DOI PMC

Obi K, et al. Relationship of phosphorylated alphasynuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp. Neurol. 2008;210:409–420. doi: 10.1016/j.expneurol.2007.11.019. PubMed DOI

Walker DG, et al. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 2013;240:190–204. doi: 10.1016/j.expneurol.2012.11.020. PubMed DOI PMC

Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605–1611. doi: 10.1212/01.wnl.0000242630.52203.8f. PubMed DOI

Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov. Disord. 2012;27:8–30. doi: 10.1002/mds.23795. PubMed DOI

Milber JM, et al. Lewy pathology is not the first signof degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79:2307–2314. doi: 10.1212/WNL.0b013e318278fe32. PubMed DOI PMC

Kanazawa T, et al. Pale neurites, premature α-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol. 2012;22:67–78. doi: 10.1111/j.1750-3639.2011.00509.x. PubMed DOI PMC

Schulz-Schaeffer WJ. Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology. 2012;79:2298–2299. doi: 10.1212/WNL.0b013e318278b6a7. PubMed DOI

Schulz-Schaeffer WJ. Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s disease? Biomolecules. 2015;5:1467–1479. doi: 10.3390/biom5031467. PubMed DOI PMC

Bousset L, et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 2013;4:2575. doi: 10.1038/ncomms3575. PubMed DOI PMC

Guo JL, et al. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154:103–117. doi: 10.1016/j.cell.2013.05.057. PubMed DOI PMC

Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009;29:3365–3373. doi: 10.1523/JNEUROSCI.5427-08.2009. PubMed DOI PMC

Ip CW, et al. AAV1/2 - induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease. Acta Neuropathol. Commun. 2017;5:11. doi: 10.1186/s40478-017-0416-x. PubMed DOI PMC

Gratwicke J, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci. Biobehav. Rev. 2013;37:2676–2688. doi: 10.1016/j.neubiorev.2013.09.003. PubMed DOI

Hale MW, Lowry CA. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology. 2013;213:243–264. doi: 10.1007/s00213-010-2089-z. PubMed DOI

Zaja-Milatovic S, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology. 2005;64:545–547. doi: 10.1212/01.WNL.0000150591.33787.A4. PubMed DOI

Stephens B, et al. Evidence of a breakdown of corticostriatal connections in Parkinson’s disease. Neuroscience. 2005;132:741–754. doi: 10.1016/j.neuroscience.2005.01.007. PubMed DOI

Goker-Alpan O, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain. 2012;135:2440–2448. doi: 10.1093/brain/aws174. PubMed DOI PMC

Nalls MA, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70:727–735. doi: 10.1001/jamaneurol.2013.1925. PubMed DOI PMC

Bras J, et al. Genetic analysis implicates APOE, SNCA and suggest lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum. Mol. Gen. 2014;23:6139–6146. doi: 10.1093/hmg/ddu334. PubMed DOI PMC

Schrag A, Siddiqui UF, Anastasiou Z, Weintraub Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol. 2017;16:66–75. doi: 10.1016/S1474-4422(16)30328-3. PubMed DOI PMC

Reply: Matters Arising 'Lewy body disease or diseases with Lewy bodies?'